Evidence map›Paper›PMID 38744470›Full record

ArticleLife science alliance2024

Modulating mycobacterial envelope integrity for antibiotic synergy with benzothiazoles.

Eva Habjan, Alexander Lepioshkin, Vicky Charitou, Anna Egorova, Elena Kazakova, Vien Qt Ho, Wilbert Bitter, Vadim Makarov, Alexander Speer

Abstract read
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Journal of bacteriology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eva HabjanDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.ORCID 0000-0003-0613-8564
Alexander LepioshkinFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), Moscow, Russia.
Vicky CharitouDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Anna EgorovaFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), Moscow, Russia.ORCID 0000-0002-6708-2421
Elena KazakovaFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), Moscow, Russia.
Vien Qt HoDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.ORCID 0000-0001-9405-7195
Wilbert BitterDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Vadim MakarovFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), Moscow, Russia makarov@inbi.ras.ru.ORCID 0000-0001-8746-2694
Alexander SpeerDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands a.speer@amsterdamumc.nl.ORCID 0000-0001-7142-5987

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing effective tuberculosis drugs is hindered by mycobacteria's intrinsic antibiotic resistance because of their impermeable cell envelope. Using benzothiazole compounds, we aimed to increase mycobacterial cell envelope permeability and weaken the defenses of

Indexed as

BenzothiazolesDrug SynergismMycobacterium marinumZebrafishAnimalsAnti-Bacterial AgentsAntitubercular AgentsCell MembraneCell Membrane PermeabilityHumansMacrophagesMicrobial Sensitivity TestsMycobacterium Infections, NontuberculousMycobacterium tuberculosisRifampinAnti-Bacterial AgentsAntitubercular AgentsBenzothiazolesRifampin

Identifiers

PMID38744470
PMCPMC11094368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.